Loading stock data…
SHC
$16.53+0.67 (+4.22%)
Market ClosedLast close Jun 9
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sotera Health Company in the Healthcare sector is trading at $16.53 with a market capitalization of $4.5B. Wall Street consensus targets $20.11 (9 analysts), implying a +21.7% move over the next 12 months. The stock is currently 17% below its 52-week high of $19.85, remaining 1.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$16.53
Potential Upside
53.4%
Whystock Fair Value$25.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$20.11+21.7%
Range$16.00 – $24.00
Fundamentals
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and N...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.15
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.86%
Volume
Today's trading volume
3.58M
Recent News
Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls
Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls
1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
3 Stocks Estimated To Be Trading Up To 44.8% Below Intrinsic Value
The United States market has shown robust performance, climbing 1.2% in the last week and 29% over the past year, with earnings projected to grow by 17% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.
The Bull Case For Sotera Health (SHC) Could Change Following Term Loan Refinancing At Lower Interest Margin
Sotera Health recently amended its First Lien Credit Agreement, securing US$1.42 billion in repriced term loans maturing in 2031 at a lower interest margin to refinance its existing term debt. This refinancing, combined with the company’s strong first-quarter results and guidance raise, underscores management’s focus on optimizing its capital structure while supporting growth investments. Next, we’ll examine how the lowered interest spread on Sotera’s refinanced term loans could influence...
A Look At Sotera Health (SHC) Valuation After Strong Q1 Beat And Upgraded Full Year Outlook
Sotera Health (SHC) is back in focus after reporting first quarter revenue of US$280 million, up 10% year on year. This result beat analyst expectations and prompted the largest full year guidance raise in its peer group. See our latest analysis for Sotera Health. Despite the strong first quarter update and a refinancing of its term loans that modestly reduced interest costs, Sotera Health’s share price is still down 11.48% year to date, even as the 1 year total shareholder return is 28.78%...